Sonnet BioTherapeutics (SONN) Competitors $4.32 +0.18 (+4.22%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$4.49 +0.17 (+3.82%) As of 07/3/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SONN vs. FLGC, SYBX, ASBP, GOVX, ALLR, PRPH, UBX, EDSA, VYNE, and MEShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Flora Growth (FLGC), Synlogic (SYBX), Aspire Biopharma (ASBP), GeoVax Labs (GOVX), Allarity Therapeutics (ALLR), ProPhase Labs (PRPH), UNITY Biotechnology (UBX), Edesa Biotech (EDSA), VYNE Therapeutics (VYNE), and 23andMe (ME). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Its Competitors Flora Growth Synlogic Aspire Biopharma GeoVax Labs Allarity Therapeutics ProPhase Labs UNITY Biotechnology Edesa Biotech VYNE Therapeutics 23andMe Flora Growth (NASDAQ:FLGC) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership. Do analysts prefer FLGC or SONN? Flora Growth currently has a consensus target price of $4.00, indicating a potential upside of 529.92%. Sonnet BioTherapeutics has a consensus target price of $20.00, indicating a potential upside of 362.43%. Given Flora Growth's higher probable upside, research analysts clearly believe Flora Growth is more favorable than Sonnet BioTherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flora Growth 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, FLGC or SONN? Sonnet BioTherapeutics has lower revenue, but higher earnings than Flora Growth. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFlora Growth$59.51M0.24-$15.91M-$0.98-0.65Sonnet BioTherapeutics$20K685.51-$7.44MN/AN/A Does the media prefer FLGC or SONN? In the previous week, Flora Growth had 2 more articles in the media than Sonnet BioTherapeutics. MarketBeat recorded 4 mentions for Flora Growth and 2 mentions for Sonnet BioTherapeutics. Flora Growth's average media sentiment score of 0.79 beat Sonnet BioTherapeutics' score of 0.00 indicating that Flora Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Flora Growth 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sonnet BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in FLGC or SONN? 36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 9.5% of Sonnet BioTherapeutics shares are owned by institutional investors. 12.6% of Flora Growth shares are owned by company insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, FLGC or SONN? Flora Growth has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Is FLGC or SONN more profitable? Sonnet BioTherapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -24.85%. Flora Growth's return on equity of -216.49% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Flora Growth-24.85% -216.49% -45.56% Sonnet BioTherapeutics N/A -777.92%-271.32% SummaryFlora Growth beats Sonnet BioTherapeutics on 9 of the 13 factors compared between the two stocks. Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.41M$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E RatioN/A21.5627.4320.22Price / Sales685.51281.76416.87118.64Price / CashN/A42.7336.8958.07Price / Book-6.097.518.035.67Net Income-$7.44M-$55.05M$3.18B$249.13M7 Day Performance286.16%4.61%2.88%3.28%1 Month Performance274.46%4.72%3.69%5.56%1 Year Performance-41.17%5.92%36.02%21.12% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics2.4575 of 5 stars$4.33+4.2%$20.00+362.4%-38.6%$12.41M$20K0.0010Gap DownHigh Trading VolumeFLGCFlora Growth3.0302 of 5 stars$0.66+0.2%$4.00+506.1%-34.9%$14.87M$59.51M-0.67280News CoverageSYBXSynlogic0.5273 of 5 stars$1.17-7.1%N/A-18.1%$14.74M$10K-0.4780Gap UpASBPAspire BiopharmaN/A$0.28-2.8%N/AN/A$14.36MN/A0.00N/AGOVXGeoVax Labs3.3807 of 5 stars$0.87-7.3%$11.10+1,168.9%-83.4%$14.34M$3.95M-0.2410Analyst DowngradeGap UpALLRAllarity Therapeutics1.1247 of 5 stars$0.90-3.2%N/A-83.1%$14.02MN/A0.0010PRPHProPhase Labs0.7585 of 5 stars$0.34-0.3%N/A-88.8%$13.96M$6.77M-0.27130UBXUNITY Biotechnology4.2153 of 5 stars$0.75-6.8%$3.75+400.0%-77.1%$13.86M$240K-0.4660Gap DownEDSAEdesa Biotech1.7582 of 5 stars$2.00+2.0%$21.00+950.0%-49.5%$13.76MN/A-1.2620Positive NewsVYNEVYNE Therapeutics3.1112 of 5 stars$0.91+2.7%$6.25+583.7%-24.6%$13.54M$500K-0.9230Positive NewsME23andMeN/A$0.50-35.3%N/A-94.1%$13.36M$208.78M-0.03770Gap DownHigh Trading Volume Related Companies and Tools Related Companies Flora Growth Competitors Synlogic Competitors Aspire Biopharma Competitors GeoVax Labs Competitors Allarity Therapeutics Competitors ProPhase Labs Competitors UNITY Biotechnology Competitors Edesa Biotech Competitors VYNE Therapeutics Competitors 23andMe Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SONN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SONN Stock Alerts